Details of the Drug-Related molecule(s) Interaction Atlas

MK-0354 Drug Info

MK-0354; 851776-28-8; UNII-4U62D8JYIQ; 4U62D8JYIQ; CHEMBL456145; 3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazole; 3-(2H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole; 1,4,5,6-Tetrahydro-3-(1H-tetrazol-5-yl)cyclopenta[c]pyrazole; 3-(2H-tetrazol-5-yl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazole; LTQYSJKGRPGMPO-UHFFFAOYSA-N; SCHEMBL1875705; GTPL5784; MolPort-009-683-033; 1,4,5,6-tetrahydro-3-(2H-tetrazol-5-yl)Cyclopentapyrazole; BCP18112; ZINC38312374; BDBM50273099; AKOS030526928; MK 0354; CS-4589

Cross-matching ID

PubChem CID

11159621

CAS Number

CAS 851776-28-8

TTD Drug ID

DMWFTRJ

General Information of Drug (ID: DMWFTRJ)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Nicotinic acid receptor (HCAR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vitamin B3	DMQVRZH	Chronic renal failure	GB61.Z	Approved	[2]
ARI-3037MO	DM9LNXS	Cardiovascular disease	BA00-BE2Z	Phase 2	[3]
SCH-900271	DMBJY1Z	Ischemic stroke	8B11.5Z	Phase 2	[4]
GSK-256073	DMMAIY2	Hyperlipidaemia	5C80	Phase 2	[5]
MK-1903	DMVJB09	Arteriosclerosis	BD40	Phase 2	[6]
NIA-114	DM3ADQW	Plaque psoriasis	EA90.0	Clinical trial	[7]
INCB19602	DMRHZBD	Type-2 diabetes	5A11	Discontinued in Phase 2	[8]
cinnamic acid	DM340FH	Discovery agent	N.A.	Investigative	[9]
5-Benzyl-1H-pyrazole-3-carboxylic acid	DMJVGUZ	Discovery agent	N.A.	Investigative	[10]
Sazetidine-A	DM68JI5	Major depressive disorder	6A70.3	Investigative	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Nicotinic acid receptor (HCAR2)	TTWNV8U	HCAR2_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	GPR109a agonists. Part 2: pyrazole-acids as agonists of the human orphan G-protein coupled receptor GPR109a. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4472-4.
2	Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miyamoto K, Greatens A, Hillebrand GG, Bissett DL, Boissy RE: The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002 Jul;147(1):20-31.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia. ACS Med Chem Lett. 2011 Nov 24;3(1):63-8.
5	GSK256073, a selective agonist of G-protein coupled receptor 109A (GPR109A) reduces serum glucose in subjects with type 2 diabetes mellitus. Diabetes Obes Metab. 2013 Nov;15(11):1013-21.
6	Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression. Sci Transl Med. 2012 Aug 22;4(148):148ra115.
7	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8	DOI: 10.1038/scibx.2010.313
9	Phenolic acids suppress adipocyte lipolysis via activation of the nicotinic acid receptor GPR109A (HM74a/PUMA-G). J Lipid Res. 2009 May;50(5):908-14.
10	Pyrazole derivatives as partial agonists for the nicotinic acid receptor. J Med Chem. 2003 Aug 28;46(18):3945-51.